Pain Management

Like other non-steroidal anti-inflammatory drugs (NSAIDs), ketorolac works on cyclooxygenase enzymes (COX) and inhibits prostaglandin synthesis.

A look at the top stories in pharmacy last week.

Opana ER was first approved in 2006 for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Pharmacists may find themselves in an ethical dilemma related to prescribing of opioids.

Brief opioid use may increase the risk of long-term use.

Due to the increasing rise in drug abuse from opioids and recent safety warnings regarding NSAIDs, practitioners are beginning to show more interest in topical agents.

Sleep deprivation could increase sensitivity to pain.

Opioid use among Afghanistan, Iraq veterans similar to general population.

Recently we have received an increasing number of requests for consults on patients undergoing hemodialysis (HD) or with end-stage renal disease (ESRD).

The analgesic effects of alcohol could lead to a new class of painkillers.

OTC medications are typically not covered making them unaffordable and less accessible to the majority of the population.

After 3 days, patients treated with methadone during surgery no longer required opioids.

Having a few alcoholic beverages may be just as effective as some pain medications from the pharmacy, according to research from a new study.

Tighter regulations surrounding opioids have presented a challenge to physicians treating chronic pain.

Buprenorphine and naloxone buccal film (Bunavail) approved for a revised indication to include use for the initiation of buprenorphine treatment for opioid dependence.

Chronic pain has been defined by the International Association for the Study of Pain as pain that persists beyond the normal tissue healing time of 3 months, and it may be classified into 3 distinct categories: nociceptive, neuropathic, and a mixture of the two.

An interdisciplinary treatment modality is especially effective when treating patients with chronic pain.

Novel investigational compound observed to treat chronic pain without side effects.

A study led by UC Irvine and Duke University, presented at the 2017 American Academy of Pain Medicine meeting in Orlando, examined the association between opioid therapy and melanoma progression in patients diagnosed with the disease.

At the American Academy of Pain Medicine’s 2017 Annual Meeting, survey results were presented that revealed the implications of naloxone use in real-world experiences with the recently approved intranasal naloxone formulation.

The meeting theme this year, Pain as a Public Health Issue, emphasizes the extent to which pain affects the US population, with more than 100 million Americans suffering from pain.

To the dismay of many health care professionals, opioid abuse has become an epidemic in the United States.

Patients with low back pain should initially seek non-drug therapy.

Prescribers and pharmacists in various clinical roles are often challenged when treating patients with comorbid chronic pain and end-stage renal disease (ESRD) or hemodialysis (HD). There is a dearth of clinical guidelines available for chronic pain management in this setting. Those selecting pharmacotherapy for patients must rely on clinical judgement, literature analysis and prudent decision making.

On February 15 2017, Governor Chris Christie of New Jersey signed legislation aimed to curb the state’s opioid addiction epidemic